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Abstract
Cancer stem cells (CSCs) possess high tumor-initiating capacity and have been reported to be resistant to therapeutics. Vice
versa, therapy-resistant cancer cells seem to manifest CSC phenotypes and properties. It has been generally assumed that
drug-resistant cancer cells may all be CSCs although the generality of this assumption is unknown. Here, we chronically
treated Du145 prostate cancer cells with etoposide, paclitaxel and some experimental drugs (i.e., staurosporine and 2
paclitaxel analogs), which led to populations of drug-tolerant cells (DTCs). Surprisingly, these DTCs, when implanted either
subcutaneously or orthotopically into NOD/SCID mice, exhibited much reduced tumorigenicity or were even non-
tumorigenic. Drug-tolerant DLD1 colon cancer cells selected by a similar chronic selection protocol also displayed reduced
tumorigenicity whereas drug-tolerant UC14 bladder cancer cells demonstrated either increased or decreased tumor-
regenerating capacity. Drug-tolerant Du145 cells demonstrated low proliferative and clonogenic potential and were
virtually devoid of CD44
+ cells. Prospective knockdown of CD44 in Du145 cells inhibited cell proliferation and tumor
regeneration, whereas restoration of CD44 expression in drug-tolerant Du145 cells increased cell proliferation and partially
increased tumorigenicity. Interestingly, drug-tolerant Du145 cells showed both increases and decreases in many ‘‘stemness’’
genes. Finally, evidence was provided that chronic drug exposure generated DTCs via epigenetic mechanisms involving
molecules such as CD44 and KDM5A. Our results thus reveal that 1) not all DTCs are necessarily CSCs; 2) conventional
chemotherapeutic drugs such as taxol and etoposide may directly target CD44
+ tumor-initiating cells; and 3) DTCs
generated via chronic drug selection involve epigenetic mechanisms.
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Introduction
The cancer stem cell (CSC) concept, that tumors contain stem-like
cancer cells, was proposed decades ago and recently revived to explain
the cellular heterogeneity in the tumor. One of the most important
criteria for defining CSCs is their enhanced ability to regenerate
transplantable tumors that histologically recapitulate the phenotypic
heterogeneity of the parental tumor [1]. As such, CSCs are often
called tumor-initiating cells. CSCs were first identified in leukemia
and, since 2003, have been reported for many human solid tumors
including glioma [2], Ewing’s sarcoma [3], and cancers of the breast
[4,5], colon [6–12], pancreas [13,14], liver [15–17], stomach [18],
lung [19,20], head and neck [21], kidney [22], and ovary [23,24].
Mounting evidence suggests that CSCs may be more resistant to
anti-cancer therapeutics, as shown in leukemic [25] and multiple
myeloma [26] stem cells. CD133
+ CSCs increase following
radiation and contribute to glioblastoma radioresistance through
preferential activation of the DNA damage checkpoint response
andanincreaseinDNArepaircapacity[27].TheCD44
+CD24
lo/2
breast CSCs are enriched in breast cancer patients who have
received adjuvant chemotherapy [28] and more resistant to some
chemotherapeutic drugs [29]. In mouse models of mammary
tumors, CSCs have also been shown to be refractory to cisplatin
treatment [30]. Furthermore, chemoresistant colon cancer cells
display CSC phenotypes [31] and CD133
+ hepatic CSCs are
chemoresistant due to preferential activation of the Akt pathway
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24397[32]. Thesenewfindings highlight potentialinvolvementof CSCs in
therapy resistance and in disease recurrence. It has been assumed
that drug-resistant cancer cells may all be enriched in CSCs
although the general applicability of this assumption remains
untested.
Immunohistochemical staining [33,34], clonogenic assays
[35,36], as well as tumor transplantation experiments [37–41]
have provided evidence that human prostate cancer (PCa) also
contains stem-like cells. Our systematic studies in xenograft
models indicate that PCa cells are heterogeneous with respect to
their tumor-initiating capacity with the CD44
+ cell population
harboring both quiescent CSCs and fast proliferating tumor
progenitors [38,42]. A fraction of CD44
+ PCa cells are slow-
cycling, can apparently undergo self-renewal, preferentially
express ‘stemness’ genes, and possess high tumorigenic and
metastatic potentials. CSCs can be further enriched using
CD44
+a2b1
hi marker profile [39] and PCa cell holoclones, in
which most cells are CD44
+a2b1
hi, contain self-renewing tumor-
initiating cells [41]. Our recent work shows that Nanog, essential
for the self-renewal and pluripotency of ES cells, is enriched in
the CD44
+ PCa cell population and functionally required for
tumor development [43]. In fact, inducible Nanog expression is
sufficient to endow CSC phenotypic and functional properties
and to promote castration-resistant PCa development [44]. A key
unanswered question is whether stem-like PCa cells may behave
like some other CSCs being resistant to therapeutics or,
alternatively, whether drug treatment would enrich PCa-initiat-
ing cells. Here we report the unexpected findings that some drug-
tolerant cancer cells are much less tumorigenic or even non-
tumorigenic. Surprisingly, the drug-tolerant Du145 PCa cell
cultures are devoid of CD44
+ cells, which, at least partially,
account for their reduced tumorigenicity.
Materials and Methods
Animal-related studies have been approved by the M.D
Anderson Cancer Center Institutional IACUC committee (ACUF
08-05-08132). All other studies presented herein were the
investigator-initiated and did not require approval from other
regulatory bodies.
Cells, reagents, and animals
Du145, PC3, and UC14 cells were obtained from ATCC and
cultured in RPMI containing 7% heat-inactivated FBS, 100 mg/
ml streptomycin, and 200 U/ml penicillin (Gibco). DLD1 cells
were obtained from ATCC and cultured in DMEM containing
7% FBS with antibiotics. Etoposide (VP16) and paclitaxel were
purchased from Sigma. Doxorubicin (Dox) and staurosporine
(STS) were bought from Biomol. WP1102 and WP1103 were two
newly synthesized paclitaxel analogs with substitutions at the 29-
OH (by the Priebe group; details to be published elsewhere).
Primary antibodies used in the current study included: rabbit mAb
to CD44 (Abcam) for Western blotting (1:1,000), mouse mAb to
CD44 (BD Pharmingen) for immunostaining (1:500), mouse mAb
to ABCG2 (Abcam; 1:500), rabbit pAb to Bcl-2 (Santa Cruz;
1:500), mouse mAbs to p21 and p27 (Santa Cruz; 1:1,1000 for
both), rabbit pAb to hTERT (Santa Cruz; 1:100), rabbit mAb to
GAPDH (Cell Signaling; 1:2,000) and mAb to b-actin (Cell
Signaling; 1:1,000). Secondary antibodies were purchased from
GE Healthcare and ECL Plus reagents were from PerkinElmer
Inc. NOD/SCID mice were initially purchased from the Jackson
Laboratories (Bar Harbor, ME) and the breeding colonies
established in our animal facility and maintained in standard
conditions according to the institutional guidelines.
Establishment of drug-tolerant cells (DTCs) and
determination of IC50 values
Du145, DLD1, and UC14 cells were initially exposed to various
drugs, in quadruplicate wells, at a range of concentrations, i.e., 0,
0.1 nM, 1 nM, 10 nM, 50 nM, 0.1 mM, 0.5 mM, 1 mM, 2 mM,
4 mM, and 10 mM. Drugs were replenished every 3 days and cells
were treated continuously for 2 weeks. Cell survival and death
were closely monitored under an inverted phase-contrast micro-
scope. At the end of a 2-week treatment, ‘optimal’ drug
concentrations were determined based on the criterion that drugs
showed significant inhibitory effects on cell expansion but did not
completely kill the whole population (,90% cell killing). The
entire experiment was repeated once. These experiments led to the
determination of optimal concentrations (indicated in the Text).
Thereafter, cancer cells were continuously cultured in the medium
containing the optimal concentration of drugs for a minimum of 3
months to establish the DTCs, which were designated as Du145-
VP16 cells, Du145-Paclitaxel cells, so on and so forth. The DTCs
were routinely cultured in the medium containing the optimal
concentrations of individual drugs.
To determine the half-maximal concentrations of inhibition (i.e.,
IC50) of parental cancer cells and the DTCs, 2.5–3.0610
5 cells were
plated in quadruplicate in 24-well plates. After overnight culture,
cellsweretreatedwithdifferentconcentrationsoftheinitialselection
drug or non-selecting drugs (to examine potential cross resistance)
for 24–48 h. At the end of treatment, viable cell numbers were
counted using trypan blue assays and the GraphPad prism 5.0
software was used to analyze data and calculate the IC50 values.
Clonal and BrdU incorporation assays,
immunofluorescence, and immunoblotting
Basic procedures for these experiments have been described in
our earlier publications [37–39,43–45]. To determine total cell
numbers,5,000cellswereplatedintriplicateorquadruplicatein12-
well plates and cultured for 10 days, with fresh medium fed every 3
days. At the end, viable cell numbers were counted using trypan
blue. For BrdU assays, cells were plated in triplicate on glass
coverslips (10,000 cells/coverslip) overnight and then pulsed with
10 mM BrdU for 4 h. At the end, cells were fixed in 4%
paraformaldehyde containing 5% sucrose for 10 minutes. Cells
were incubated for 20 min in 1% Triton-100 and then denatured,
neutralized, blocked, and incubated with monoclonal anti-BrdU
antibody (1:100) for 1 h at 37uC followed by goat anti-mouse IgG-
Alexa Fluor 594 (30 min at 37uC). A total of 500–1000 cells were
counted per coverslip and two coverslips were counted for each cell
type to determine the percentage of proliferating (i.e., BrdU
+) cells.
For clonal analysis, 100 cells were plated in triplicate in 6-well
plates and cultured for 10 days with fresh medium fed every 3
days. At the end, both holoclones and meroclones [41] were
enumerated and the results were presented as the cloning
efficiency. Paraclones contained large and senescent cells [41]
and generally had ,20 cells and therefore were not quantified.
Immunofluorescence staining of CD44 was performed as de-
scribed [38,45]. For Western blotting. parental Du145 and various
drug-tolerant Du145 cells were harvested to prepare whole cell
lysate in Western blotting analysis of the molecules indicated in the
figure panels. In some experiments, Du145-VP16 cells were first
treated with various concentrations of trichostatin A (TSA) or 59-
aza-deoxycytidine (Aza) for 72 h.
Establishment of GFP-tagged drug-tolerant DU145 cells
Briefly, 293FT packaging cells [43] were transfected with
pLL3.7-GFP lentiviral vector [43] together with the packaging
Drug-Tolerant Cancer Cells, CD44, and Epigenetics
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collected 48–72 h later, centrifuged at 3,000 rpm, passed through
a 0.45 mm filter to remove debris and finally subjected to
ultracentrifugation (20,000 rpm62 h at 4uC). Drug-tolerant
DU145 cells were then infected with the virus at MOI (multiplicity
of infection) of 20–25.
Subcutaneous (s.c) and orthotopic tumor experiments
Basic procedures were previously described [37–39,41,43,46].
Briefly, parental and drug-tolerant Du145 (and other) cells at
different numbers were injected in 50% Matrigel s.c into the flanks
of NOD/SCID mice. When the largest tumor(s) in any group must
be terminated by IACUC regulations or the tumor-bearing
animals became moribund, all animals in that group were
sacrificed and tumors harvested. For orthotopic implantation,
animals were anesthetized and cells were injected in a 20-ml
medium-Matrigel mixture (1:1) into the dorsal prostate. When
tumor burden became obvious (by palpation), the experiment was
terminated, animals sacrificed, and primary tumors together with
several organs (i.e. lung, liver, spleen, pancreas, kidney, etc) were
dissected and examined for micro and macrometastasis (i.e., GFP
+
foci) under a Nikon epifluorescence microdissection microscope.
CD44 knockdown experiments
shRNA-mediated knockdown was performed as recently
described [43,46]. Briefly, 293FT packaging cells were transfected
with either pGIPz CD44-shRNA lentiviral vector or pGIPz-NS
control vector. The virus-containing culture medium was collected
72 h post transfection, centrifuged at 3,000 rpm, filtered through a
0.45 mm-syringe filter, and finally subjected to ultracentrifugation
(20,000 rpm62 h at 4uC). The viral pellet was reconstituted in the
OPTI-MEM medium and used to infect HT1080 fibrosarcoma
cells to determine the viral titer. Then Du145 cells were infected
with the pGIPz-NS or pGIPz-CD44shRNA viruses at an MOI of
20, and, 24–48 h later, were used in either in vitro characteriza-
tions or in vivo tumor experiments.
CD44 overexpression experiments
The basic retroviral procedure was previously described [45].
Briefly, retroviral vectors, including control vector pBabe-GFP
and pBabe-CD44 (Addgene, Cambridge, MA) were transfected
into the Ampho-Phoenix 293 cells (ATCC). 48–72 h post
transfection, virus-containing culture medium was collected,
centrifuged at 3,000 rpm, filtered through a 0.45 mm-syringe
filter, and finally subjected to ultracentrifugation (22,000 rpm62h
at 4uC). The viral pellet was reconstituted in the OPTI-MEM
medium and used to infect drug-tolerant Du145 cells for 24–48 h,
which were then used in both in vitro and in vivo experiments.
Therapeutic treatment of orthotopic PC3 tumors with
paclitaxel
The basic procedure for therapeutic experiments was recently
described [46]. Briefly, PC3-GFP cells were implanted in the
dorsal prostate (DP) of male NOD/SCID mice (500,000 cells/DP;
n=10). Three weeks later, 5 animals per group were injected,
intravenously, with 15 mg/kg body weight of paclitaxel or vehicle
control (PBS). The injections were repeated every week for two
more weeks (i.e., a total of 3 injections) and animals were
terminated 49 days after tumor cell implantation. The DP tumors
were dissected out, imaged, and weighed whereas several organs,
including the lung, pancreas, lymph node, liver, and brain, were
examined for metastasis on a dissecting epifluorescence micro-
scope [46].
Analysis of ‘stemness’ gene expression profiles by
quantitative reverse transcriptase – polymerase chain
reaction (qPCR)
The basic procedure for qPCR analysis was recently described
[44,46]. Briefly, total RNA was extracted from Du145 and Du145-
VP16 cells using an RNeasy RNA-purification kit (Qiagen,
Valencia, CA). The ABI High-Capacity cDNA Archive Kit
(Applied Biosystems, Carlsbad, CA) and random hexamers were
used for cDNA synthesis. qPCR was performed by the M.D.
Anderson Science-Park Molecular Biology Core Facility using an
ABI Prism 7900HT (Applied Biosystems). File Builder 3.1 software
(Applied Biosystems) was used to design PCR primers and probes.
Human gene-specific primer pairs were used for expression
profiling by the SYBRH Green method. The experimental Ct
(cycle threshold) was calibrated against that of 18S control
product. All amplifications were performed in triplicate. The
DDCt method was used to determine the amount of gene product
relative to that expressed in parental Du145 cells (1-fold, 100%).
Statistical analyses
GraphPad prism 5.0 software and F-test were used to compare
the IC50 values. Unpaired t-test was used to compare differences in
cell numbers, BrdU
+% cells, cloning efficiency, CD44
+% cells, and
tumor weights. Fisher’s Exact Test was used to compare incidence
and latency.
Results
Chronic sublethal drug treatment led to drug-tolerant
cancer cells
Clinically, many cancer patients are often treated CHRONI-
CALLY by anti-cancer therapeutics. The best example perhaps is
CML (chronic myelogenous leukemia) patients who must take
imatinib (Gleevec) continuously for years [47]. Furthermore,
metronomic chemotherapy – a form of chemo administration
characterized by frequent, often daily, extended administration of
small doses of conventional chemodrugs without major breaks
[48], is emerging as a standard therapeutic regimen for many
cancers. Based on the assumptions that CSCs may have a special
advantage of surviving therapeutics and are likely the cells that
mediate drug resistance, we tested whether cancer cells that have
survived CHRONIC drug treatment may all possess CSC
properties. We first treated Du145 prostate cancer (PCa) cells
with two clinical drugs, i.e., etoposide (VP16) and paclitaxel
(Taxol) as well as three experimental drugs, staurosporine (STS), a
promiscuous protein kinase inhibitor, and two newly synthesized
paclitaxel analogs termed WP1102 and WP1103 (details to be
presented elsewhere). As described in Methods, we first treated
Du145 cells with these five drugs at a range of 10 concentrations
for 2 weeks to determine the ‘optimal’ sublethal concentrations at
which drugs significantly inhibited tumor cell expansion but did
not kill the entire population. Using this chronic treatment
protocol that ‘mimics’ metronomic treatment in the clinic, we
determined the optimal concentrations, in Du145 cells, of VP16,
paclitaxel, STS, WP1102, and WP1103 at 1.25 mM, 50 nM,
7 nM, 5 nM, and 25 nM, respectively. Du145 cells were
subsequently cultured, continuously, in the medium containing
the optimal concentrations of drugs for ,3 months. The resultant
drug-tolerant cell (DTC) lines were designated as Du145-VP16,
Du145-Paclitaxel, Du145-STS, Du145-WP1102, and Du145-
WP1103 cells, respectively.
To determine whether drug-tolerant Du145 cells were truly
tolerant of the original selection drugs, we treated parental and
Drug-Tolerant Cancer Cells, CD44, and Epigenetics
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As shown in Fig. 1, drug-tolerant Du145 cells were generally more
resistant than parental Du145 cells to the selection drugs. Thus,
Du145-VP16 cells were .10 times more resistant than Du145 cells
to VP16 (IC50 values being 0.78 mM for Du145 and 9.17 mM for
Du145-VP16 cells). Du145-Paclitaxel cells were ,7 times more
resistant to paclitaxel than Du145 cells (Fig. 1, A and C). Similarly,
Du145-WP1103 cells were nearly 30 times more resistant to
WP1103 than Du145 cells (Fig. 1B–C). Finally, Du145-STS and
Du145-WP1102 cells were approximately 1.5 and 3 times more
resistant to STS and WP1102, respectively, than unselected
Du145 cells (Fig. 1B–C). Hence, the differential drug resistance
among the established DTCs ranked Du145-WP1103.Du145-
VP16.Du145-Paclitaxel.Du145-STS<Du145-WP1102.
Subsequently, we exposed Du145-VP16 cells to three non-
selecting drugs, i.e., paclitaxel, STS, and doxorubicin (Dox). As
shown in Fig. 2, Du145-VP16 cells were more resistant (than
parental Du145 cells) to paclitaxel (,4 fold), STS (1.5 fold), and
Dox (13 fold), suggesting that the DTCs were also cross-resistant to
other non-selecting drugs.
Using similar strategies, we also established drug-tolerant DLD1
colon (Fig. 3) and UC14 bladder (not shown) cancer cells. In DLD1
cells, the optimal concentrations for VP16, paclitaxel, WP1102, and
WP1003 were determined to be at 2.5 mM, 100 nM, 120 nM, and
100 nM, respectively. As shown in Fig. 3, the established DLD1-
VP16, DLD1-Paclitaxel, DLD1-WP1102, and DLD1-WP1103
cells were resistant to the respective selecting drugs. Furthermore,
DLD1-VP16 cells also showed cross resistance to paclitaxel and
Figure 1. Drug-tolerant Du145 cells were more resistant to the selection drugs. A–B. Parental Du145 and drug-tolerant Du145 cell lines
selected with two clinical drugs (A) or three experimental drugs (B) were exposed, side-by-side, to the respective selection drugs (e.g., Du145-VP16
cells to VP16 and Du145-Paclitaxel cells to paclitaxel) at the concentrations (transformed into logarithm) indicated. Y-axis represents cell growth
inhibition (%). C. Tabulated presentations of IC50 values (see Materials & Methods) and corresponding 95% CI (confidence interval) of Du145 cells and
drugs-tolerant Du145 cells in response to the five drugs indicated. Values were calculated from data obtained in A and B.
doi:10.1371/journal.pone.0024397.g001
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resistant to the selection drugs (i.e., paclitaxel, STS, VP16, Dox,
WP1102, and WP1103), than the parental UC14 cells (not shown).
Drug-tolerant Du145 cells were surprisingly less
tumorigenic than parental Du145 cells
We hypothesized that the DTCs might possess CSC properties
and be more tumorigenic in vivo. Much to our surprise, all drug-
tolerant Du145 cells subcutaneously (s.c) injected into the NOD/
SCID mice demonstrated much reduced tumor-initiating capacity
when compared to the same number of parental Du145 cells,
which showed a tumor-initiating frequency (TIF) of ,1/175
(Table 1). Injection of increasing numbers of parental Du145 cells,
expectedly, led to reduced latency (Table 1). In contrast, Du145-
VP16 cells showed a TIF of ,1/62,000 and, at 100,000 cells
injected, tumor latency was more than twice as long as for the
same number of Du145 cells (Table 1). In fact, both Du145-
Paclitaxel and Du145-WP1103 cells were non-tumorigenic up to
10,000 (for Du145-WP1103) and 100,000 (for Du145-Paclitaxel)
cells implanted (Table 1). Even for Du145-STS and Du145-
WP1102 cells, which showed the lowest IC50 differentials (Fig. 1B–
C), reduced tumor incidence with TIF of 1/971 and 1/45,787,
respectively, and smaller tumors were also observed (Table 1).
To determine whether tumor implantation site might have an
effect on the differential tumorigenicity observed, we established
GFP-tagged Du145 parental and drug-tolerant Du145 cells and
implanted equal numbers (i.e., 500,000) of cells orthotopically in
the dorsal prostate (DP) of the male NOD/SCID mice. When the
experiment was terminated 75 days post tumor cell injections, we
observed that Du145-VP16 and Du145-STS cells generated
smaller tumors than parental Du145 cells (Fig. 4A). In fact, both
Du145-Paclitaxel and Du145-WP1103 cells were non-tumorigenic
in the DP tumor regeneration model (Fig. 4A). Significantly,
parental Du145 cells metastasized to multiple organs including
lymph nodes, kidney, pancreas, liver, lung, and spleen whereas
drug-tolerant Du145 cells lacked apparent metastasis to any of
these organs (Fig. 4B–C; data not shown).
Drug-tolerant DLD1 cells also showed reduced
tumorigenicity whereas drug-tolerant UC14 cells
demonstrated drug-dependent changes in tumor-
initiating capacity
To determine whether the reduced tumorigenicity associated
with drug-resistant cells is restricted only to Du145 cells, we
similarly injected, s.c., increasing numbers of parental DLD1 and
four drug-tolerant DLD1 cell lines into the NOD/SCID mice. As
shown in Table S1, the drug-tolerant DLD1 cells, though
displaying similar tumor incidence, regenerated significantly
smaller tumors compared to parental DLD1 cells at the same
cell numbers.
We carried out similar limiting-dilution tumor experiments in 6
drug-selected UC14 cells (Table S2). In contrast to drug-tolerant
Du145 and DLD1 cells, which uniformly demonstrated reduced
tumorigenic potential, 4 of the 6 drug-tolerant UC14 cells (Table
S2; shadowed brown) demonstrated enhanced tumor-regenera-
tion capacity compared to the same number of parental UC14
cells. Interestingly, two drug-tolerant UC14 cell lines also
regenerated much smaller tumors than the same number of
parental UC14 cells (Table S2; shadowed pink). These results
indicate that drug-tolerant UC14 cells are either more or less
tumorigenic than the parental cells, depending on the initial
selection drugs.
Drug-tolerant Du145 cells were less proliferative and
showed low cloning efficiency
Since it was quite unexpected that some drug-tolerant cancer
cells showed reduced tumor-regenerating capacity, we subse-
quently focused on drug-tolerant Du145 cells in attempt to
uncover potential mechanisms. We consistently observed that most
Figure 2. Drug-tolerant Du145 cells were cross-resistant to non-selecting drugs. Du145-VP16 cells were treated with paclitaxel (A), STS (B),
and doxorubicin (Dox; C) at the concentrations [log] indicated. Results are presented as % inhibition and IC50 (D) were determined as in Figure 1.
doi:10.1371/journal.pone.0024397.g002
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compared to Du145 cells. Indeed, in a prospective 10-day
experiment measuring live cell numbers, we observed that all
drug-tolerant Du145 cells, except Du145-WP1102 cells, showed
much lower end-point live cell numbers (Fig. 5A), suggesting that
DTCs were less proliferative and/or more susceptible to cell
Figure 3. Drug-tolerant DLD1 cells were resistant to selecting and non-selecting drugs. Parental and drug-tolerant DLD1 cell lines
selected with optimal concentrations (see Text) of VP16, paclitaxel, WP1102, and WP1103, were exposed, side-by-side, to the respective selection
drugs at the concentrations (transformed into logarithm) indicated (A). Y-axis represents cell growth inhibition (%). B. Tabulated presentations of IC50
values and corresponding 95% CI (confidence of intervals) of parental DLD1 cells and drug-tolerant DLD1 lines in response to both selecting and non-
selecting drugs.
doi:10.1371/journal.pone.0024397.g003
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directly measure cell proliferation. As shown in Fig. 5B, drug-
tolerant Du145 cells exhibited lower proliferative indices (i.e., %
BrdU
+ cells). Interestingly, even Du145-WP1102 cells demon-
strated a lower proliferative index (Fig. 5B) although these cultures
showed similar total live cell numbers to parental Du145 cells
(Fig. 5A). Remember that Du145-WP1102 cells also displayed
relatively less reduction in tumor-initiating capacity compared to
other drug-tolerant Du145 cells (Table 1). It is possible that
Du145-WP1102 cells proliferated less but also had less spontane-
ous cell death, thus resulting in similar end-point live cell numbers
(Fig. 5A) and less pronounced decreases in tumorigenicity
(Table 1). Indeed, we consistently observed that Du145-WP1102
cells, chronically selected using 5 nM WP1102 compound, showed
less floating and apoptotic cells in the culture flasks compared with
Du145-WP1103 cells (not shown), which were chronically selected
using 25 nM WP1103 compound. Finally, we observed that all
drug-tolerant Du145 cells demonstrated lower cloning efficiencies
than the parental Du145 cells (Fig. 5C).
Consistent with reduced cell proliferation, drug-tolerant Du145
cells showed increased levels of two cyclin-dependent kinase
inhibitors, p21 and p27, especially in Du145-Paclitaxel and
Du145-WP1103 cells (Fig. 6A), the two cell lines that completely
lacked tumorigenicity (Table 1). The p27 levels were also elevated
in all three other drug-tolerant Du145 cell lines (Fig. 6A).
Intriguingly, the significantly increased p27 protein band in
Du145-Paclitaxel and Du145-WP1103 cells migrated slightly
faster than the protein in other cell lines (Fig. 6A). Future studies
will clarify this potentially interesting observation. In contrast to
p21 and p27, Bcl-2, an anti-apoptotic protein, showed less, albeit
dramatic decrements, again, in the two non-tumorigenic Du145
lines, i.e., Du145-Paclitaxel and Du145-WP1103 (Fig. 6A).
Drug-tolerant Du145 cultures showed reduced numbers
of, or were devoid of, CD44
+ cells
Several pieces of evidence suggest that diminished tumor-
regenerating capacity in drug-tolerant Du145 cells may involve, in
addition to compromised proliferative potential perhaps mediated
Table 1. Drug-tolerant Du145 cells possess much reduced tumorigenic potential.
Cell type
a Cell# Incidence (%)
b TIF
c Latency(d)
d Termination(d)
d Weight (g)
e
Du145 100 7/7 (100) 1/175 (1/66–1/467) 63 90 0.0760.03 (0.03–0.12)
1000 7/8 (87.5) 36 60 0.4260.33 (0.10–0.95)
10000 8/8 (100) 27 59 0.5060.35 (0.12–0.97)
100000 7/8 (87.5) 21 52 0.3960.17 (0.18–0.65)
Du145-VP16 100 1/8 (12.5) 1/62,453 (1/26,455–1/147,436) 92 117 1.45
1000 0/8** 60
10000 0/8** 59
100000 5/6 (83.3) 51** 52 0.0660.05 (0.02–0.14)**
Du145-VP16 (2 mo.)# 1000 1/6 (16.7)* 1/30,110 (1/7,199–1/125,948) 83 127 0.01
10000 1/6 (16.7)* 45 127 0.2
Du145-STS 100 1/8 (12.5) 1/971 (1/421–1/2,241) 52* 90 0.16
1000 5/8 (62.5) 58* 66 0.0760.02 (0.04–0.09)*
10000 3/8 (37.5)* 48* 66 0.1360.14 (0.05–0.29)*
Du145-Paclitaxel 100 0/8** 105
1000 0/8** 60
10000 0/8** 60
100000 0/6** 52
Du145-WP1102 100 2/4 (50) 1/45,787 (1/15,313–1/136,901) 58 90 0.0360.01 (0.02–0.04)*
1000 2/4 (50) 58** 66 0.3760.13 (0.27–0.46)
10000 2/4 (50) 58** 66 0.1160.12 (0.02–0.19)*
100000 3/4 (75) 31* 52 0.1960.24 (0.01–0.46)
Du145-WP1103 100 0/8** 99
1000 0/8** 60
10000 0/8** 60
Du145-WP1103 (2 mo.)# 1000 0/6** 108
10000 0/6** 108
aParental Du145 or drug-tolerant Du145 cells were s.c implanted in 50% Matrigel, at the numbers indicated, in NOD/SCID mice. In the two experiments marked by #,
cells were first cultured in drug-free medium for 2 months prior to injections.
bTumor incidence (% of tumor development/injections).
cTumor-initiating frequency, as determined using the L-Calc
TM software (Stemcell Technologies). The ranges were indicated in the parentheses.
dTumor latency (mean time in days from injection to when tumors were first palpated) and termination time (days from injection to when animals were sacrificed).
eMean 6 S.D (ranges in parentheses). Note that tumor weights sometimes varied greatly among different cell number groups. For statistical analyses, Fisher’s Exact Test
was used to compare tumor incidence and Student t-test was used to compare tumor weights and latencies.
*P,0.05;
**P,0.01, when compared with the parental Du145 cells of the same number.
doi:10.1371/journal.pone.0024397.t001
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initiating cells. When we examined drug-tolerant Du145 cells for
the levels of hTERT, which is essential for normal prostate stem/
progenitor cells as shown by our recent studies [45], we found that
Du145-Paclitaxel and Du145-WP1103 cells, which lacked tumor-
igenic potential, lost hTERT expression (Fig. 6A). Our previous
Figure 4. Orthotopically implanted drug-tolerant Du145 cells showed reduced tumorigenic and metastatic potential. A. GFP-tagged
parental or drug-tolerant Du145 cells were implanted (500,000 cells/injection), in 50% Matrigel, in the DP of NOD/SCID mice. All animals were
terminated 75 days post implantation. Shown are tumor incidence and tumor weights (mean 6 S.D; statistics not applicable due to relatively small
numbers of animals). B–C. Representative tumor and organ images from a tumor-bearing animal in the Du145 (B) and Du145-VP16 (C) group,
respectively. All images were acquired using a Nikon microdissecting epifluorescence microscope at 0.756and the boxed area in B (the lung GFP
image) represents an enlargement showing GFP
+ spots in the lung.
doi:10.1371/journal.pone.0024397.g004
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potential of Du145 cells largely resides in the CD44
+ cell fraction
[38,39] and it has recently been shown by one of our groups that
paclitaxel conjugated to hyaluronic acid, designed to specifically
target the CD44-expressing cells, exhibited potent anti-ovarian
cancer effects [49].
The above discussions raised the possibility that perhaps CD44
+
cells and/or CD44 expression were reduced or ablated in drug-
tolerant Du145 cell lines. To test this possibility, we carried out
both Western blotting and immunofluorescence experiments.
Remarkably, both Du145-Paclitaxel and Du145-WP1103 cultures
completely lacked CD44
+ cells (Fig. 6B–D). Du145-VP16 and
Du145-STS cultures also showed reduced CD44 protein levels
(Fig. 6B) and numbers of CD44
+ cells (Fig. 6C–D). By contrast,
Du145-WP1102 cells, which retained some tumor-initiating
capacity (Table 1), showed similar levels of CD44 protein
expression to (Fig. 6B) or slightly more CD44
+ (many faintly
positive) cells (Fig. 6C–D) than parent Du145 cultures. Hence, the
extent to which CD44
+ cells were ablated in drug-tolerant Du145
cultures appeared to correlate well with the level of reduction in
their tumorigenic potential. In contrast to CD44, ABCG2 protein
(Fig. 6B) or ABCG2
+ cells (not shown), which constituted ,1% of
total Du145 cells [37], did not show consistent and significant
changes in drug-tolerant Du145 cells.
Requirement of CD44 in Du145 cell tumorigenicity
The above surprising finding that drug-induced reduction/loss
of CD44
+ cells correlates with reduction/loss of tumorigenic
potential in Du145 DTCs, is fully consistent with our earlier
studies showing that the CD44
+ PCa cells are more tumorigenic
and metastatic than the corresponding CD44
2 cells [38,39]. To
prospectively determine whether CD44 is causally involved in PCa
cell tumorigenicity, we infected parental Du145 cells with a
lentiviral vector encoding CD44 shRNA (CD44-shRNA) or a non-
silencing shRNA (NS-shRNA). CD44-shRNA reduced CD44
protein (Fig. 7A, inset) and inhibited Du145 cell proliferation as
evidenced by reduced % of BrdU
+ cells (Fig. 7A–B) resulting in
reduced live cell numbers (Fig. 7C). When implanted either s.c or
orthotopically, the CD44-shRNA infected Du145 cells generated
significantly smaller tumors [46].
We then performed the reciprocal gain-of-function experiments
by overexpressing CD44 in drug-tolerant Du145 cells. Specifically,
we infected the Du145-VP16 cells with pBabe-CD44, which led to
increased CD44 expression compared to Du145-VP16 cells
infected with pBabe-GFP (Fig. 7D, inset). CD44 re-expression in
Du145-VP16 cells enhanced cell proliferation as revealed by BrdU
incorporation assays (Fig. 7D–E), resulting in increased live cell
numbers (Fig. 7F). Pilot studies indicated that CD44 overexpres-
sion in Du145-VP16 slightly increased tumorigenicity (tumor
incidence was 1/4 vs. 4/6 in Du145-VP16/pBabe.GFP and
Du145-VP16/pBabe.CD44, respectively).
The above results (Fig. 7) suggest that a reduction in CD44
+
cells is, at least partially, involved in the reduced tumorigenicity of
drug-tolerant Du145 cells. These observations also imply that
conventional drugs such as etoposide and Taxol may directly
target tumor-initiating cells. To further explore this latter point, we
employed PC3 cells, which are all CD44
+ [38], to establish
orthotopic tumors in the mouse prostate. After tumors developed
for ,3 weeks, we then performed a therapeutic experiment via i.p
(intra-peritoneal) injection of paclitaxel. Consistent with the idea
that Taxol may directly target CD44
+ PCa cells, the intravenously
injected paclitaxel greatly inhibited PC3 tumor growth (Fig. 7G) as
well as metastasis to the lung (Fig. 7H), pancreas and many other
organs (not shown).
Gene expression changes in drug-tolerant Du145 cells
To further understand what molecular changes might have
occurred in drug-tolerant cells, we performed a stem cell
SuperArray gene expression analysis of ,20 ‘stemness’ genes,
including ALDH1A1 (the major isoform that mediates the
Aldeflour phenotype), BCL-2, CD24, CD29 (integrin b1), CD44,
CD49b (integrin a2), c-KIT, CSF-1R, CXCR4, ITGB3 (integrin
b3), NANOG, NKX3.1, OCT-4, PROM-1 (CD133), SOX2,
hTERT, TGFB1, TGFBR2, and WNT4, in Du145 and Du145-
VP16 cells (Fig. 8A). Consistent with our Western blotting and
immunostaining results (Fig. 6), CD44 mRNA was significantly
Figure 5. Drug-tolerant Du145 cells were less proliferative and
showed low cloning efficiency. A. Quantification of numbers of
viable cells. Parent and drug-tolerant Du145 cells were plated, in
quadruplicate, in 12-well plates (5,000 cells/well) and viable cells were
quantified using Trypan blue exclusion assay 10 days post plating. B.
Quantification of % BrdU
+ cells (see Materials & Methods). C.
Determination of cloning efficiency. Parent and drug-tolerant Du145
cells were plated, in quadruplicate, in 6-well plates (100 cells/well) with
fresh medium replenished every 3 days. The numbers of holoclones and
meroclones were determined 10 days post plating. In all data, bars
represent the mean 6 S.D and statistical analyses were conducted
using Student t-test (*, P,0.05; **, P,0.01).
doi:10.1371/journal.pone.0024397.g005
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and TGFBR2 were also significantly reduced (Fig. 8A). The
mRNA levels of NANOG and CSF-1R showed a reducing trend
but the decrease was not statistically significant (Fig. 8A). Most
surprisingly, 6 molecules analyzed, ALDH1A1, BCL-2, CXCR4,
OCT-4, SOX2, and WNT4, showed significantly increased
mRNA levels in Du145-VP16 cells. These results indicate that
the drug-tolerant PCa cells show both decreases and increases in
‘stemness’ genes.
Evidence for epigenetic mechanisms in generating DTCs
Recently, Sharma et al [50], while modeling the acute response
of human lung cancer cells to chemotherapeutic drugs, detected a
small population of reversibly drug-tolerant cells that possessed an
altered chromatin state that involved the KDM5A histone lysine
demethylase. To determine whether our DTCs were ‘permanent-
ly’ changed by chronic drug exposure, we cultured Du145-VP16
and Du145-WP1103 cells in drug-free (DF) medium for 2 months
and performed tumor experiments. Such DF-2 month ‘reversion’
experiments revealed that Du145-VP16 cells were still much less
tumorigenic and Du145-WP1103 cells still failed to regenerate
tumors (Table 1, marked by #; Fig. 8B). However, when we
cultured the Du145-VP16 cells in DF medium for 3 months and
injected 10,000 such cells into the NOD/SCID mice, we observed
6/8 tumors (Fig. 8B) with mean tumor weight of 0.7660.24 g,o f
which both tumor incidence and weight were close to those in the
parental Du145 cells (Table 1).
The above tumor experiments suggest that the reduced
tumorigenicity of drug-tolerant Du145 cells is reversible and
may also involve epigenetic mechanisms. To explore this point, we
treated Du145-VP16 cells with HDAC (histone deacetylase)
inhibitor TSA (trichostatin A) or DNA methyltransferase inhibitor
59-aza-deoxycytidine (Aza), as we previously described [43]. Both
treatments significantly increased the protein levels of CD44, E-
cadherin, and KDM5A (Fig. 8C–D). When we injected 10,000
Aza-treated Du145-VP16 cells, we observed 3/10 tumors (Fig. 8B).
These results thus implicate epigenetic mechanisms in chronic
drug-induced DTC generation.
Discussion
In this study, we present several surprising and interesting
findings related to cancer cell drug resistance (tolerance). The most
unexpected finding is that some drug-tolerant cancer cells,
contrary to the general assumption, possess much reduced
tumor-propagating capacities, the most important functional assay
to define the CSC activity [1,42,51]. Therefore, both Du145 PCa
and DLD1 colon cancer cells chronically selected by multiple
Figure 6. Molecular changes and reduced CD44
+ cells in drug-tolerant Du145 cell cultures. A. Whole cell lysate from the cell types
indicated was used in Western blotting of p21, p27, Bcl-2, and hTERT and the blot was reprobed for b-actin. NS, non-specific. B. Western blotting of
CD44 and ABCG2. The blot was reprobed for b-actin and GAPDH. C–D. Du145 and drug-tolerant Du145 cells were plated on glass coverslips and
stained for CD44 using monoclonal antibody. Shown are representative images (C) and quantification of CD44
+ cells (D; mean 6 S.D, *, P,0.01).
doi:10.1371/journal.pone.0024397.g006
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tial. In contrast to Du145 and DLD1 cells, 4 of the 6 drug-tolerant
UC14 bladder cancer cells show increased tumor-regeneration
capacity but 2 drug-tolerant UC14 cell lines also display decreased
tumorigenic potential. These observations suggest that DTCs may
not necessarily always be endowed with CSC phenotypes or
properties; on the contrary, DTCs may actually be depleted of
tumor-initiating cells. Our findings are consistent with the
emerging evidence that CSCs may have their unique Achilles’
heel and CAN be preferentially eliminated by certain interventions.
For example, glioblastoma CSCs are very sensitive to temozolo-
mide [52] or blocking L1CAM signaling [53]; ovarian CSCs in the
side population are sensitive to TNFa [54]; colon CSCs can be
efficiently killed by cd T lymphocytes [55]; and breast CSCs are
selectively targeted by salinomycin [56], metformin [57], or
conventional chemodrugs [58].
The other surprising and remarkable finding of the present
study is that etoposide and taxanes, the two chemotherapy drugs
commonly used in the clinical treatment of advanced PCa and
some other cancers, preferentially deplete the CD44
+ Du145
tumor cell population that is known to be enriched in tumor-
initiating cells [38,39]. Our results bear resemblance to recent data
by Aulmann et al [58] showing that conventional chemothera-
peutic drugs such as docetaxel and doxorubicin can efficiently
target the CD44
+CD24
2 breast CSCs. In our studies, both
paclitaxel and the paclitaxel analog, WP1103, appear to have
Figure 7. CD44 knockdown and overexpression in Du145 cells inhibits and promotes, respectively, cell proliferation. A–C. CD44
knockdown experiments. Du145 cells infected with the control (NS) or CD44 shRNA lentivectors (MOI 20; 72 h) were plated (10,000/well) in triplicate,
pulsed by BrdU for 4 h, and processed for BrdU staining (see Materials & Methods). Shown in (A) is the quantification of BrdU
+ cells from a total of 500
cells counted for each and in (B) are representative images (6400). Inset, Western blot showing reduced CD44 protein expression in Du145 cells
infected with CD44-shRNA (lane 2) compared with the cells infected with NS-shRNA (lane 1). For experiments in C, Du145 cells infected with the
control (NS) or CD44 lentivector were plated (5,000/well) in quadruplicate on day 0. At the end of day 2, 4, 6, and 8, cells were dissociated and
counted by Trypan blue exclusion. Plotted are the live cell numbers (mean 6 SD) as a function of time. *P=0.019; **P=0.003 (Student’s t-test). D–F.
CD44 overexpression experiments. Du145-VP16 cells infected with GFP or CD44 retroviral vectors (MOI 20; 72 h) were plated (10,000/well) in
triplicate, pulsed by BrdU for 4 h, and processed for BrdU staining. Shown in (D) is the quantification of BrdU
+ cells from a total of 500 cells counted
for each condition and in (E) are representative images (6400). Inset, Western blot showing increased CD44 protein expression in Du145-VP16 cells
infected with pBabe-CD44 (lane 2) compared with the cells infected with pBabe-GFP (lane 1). For experiments in F, Du145-VP16 cells infected with the
GFP or CD44 retroviral vectors were plated (5,000/well) in quadruplicate on day 0. At the end of day 2, 4, 6, and 8, cells were dissociated and counted
by Trypan blue exclusion. Plotted are the live cell numbers (mean 6 SD) as a function of time. *P=0.035; **P=0.028. G–H. Paclitaxel inhibits PC3
orthotopic tumor growth (G) and metastasis (H). Presented in (G) is the tumor weight (mean 6 S.D; n=5 for each group). Tumor incidence is the
same (i.e., 5/5) for both groups. Shown in (H) are representative phase and GFP microphotographs of lung metastases, i.e., GFP
+ foci.
doi:10.1371/journal.pone.0024397.g007
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+ Du145 cells and the resultant drug-
resistant cells essentially lack tumorigenic potential. VP16 and
STS partially eradicate CD44
+ Du145 cells and the resultant
DTCs display only a partial reduction in tumor-initiating capacity.
In contrast, WP1102, another paclitaxel-related compound, does
not significantly affect the abundance of CD44
+ cells, and
consequently, Du145-WP1102 cells retain notable tumorigenic
ability. It is possible that WP1102, which is structurally similar to
WP1103, is not as potent as WP1103 because the ‘optimal’
concentration of WP1102 chosen for the study was lower than that
of WP1103. Regardless, the extent to which CD44
+ Du145 cells
are depleted correlates well with the reduction in tumorigenicity of
DTCs. Importantly, prospective knockdown of CD44 in Du145
cells greatly inhibits Du145 cell proliferation and tumor regener-
ation. Knockdown of CD44 in several other PCa models including
PC3, LAPC4, and LAPC9 also significantly inhibits tumor
development and/or metastasis [46]. By contrast, overexpression
of CD44 in drug-tolerant Du145 cells enhances cell proliferation
and slightly restores tumorigenicity. These observations not only
corroborate our earlier contention that the CD44
+ PCa cell
population harbors tumor-initiating cells, but also establish
requirements and the importance of CD44 and CD44
+ cells in
PCa development, consistent with other studies implicating
critical/functional roles of CD44 in various CSCs and tumor
systems including leukemic stem cells [59,60], colon CSCs [10],
gastric CSCs [18], and ovarian tumors [61]. It should be pointed
out that in drug-tolerant DLD1 cells, we did not observe a
significant reduction in CD44 protein levels or CD44
+ cells (Yan
et al., unpublished observations), suggesting that drug-induced
CD44 depletion may be cell type-dependent.
The third surprising finding of great interest is that drug-
tolerant Du145 cells show both decreases and increases in many
stem cell-associated molecules, implicating epigenetic mechanisms
in chronic drug selection-engendered DTCs. Indeed, although
drug-tolerant Du145-VP16 cells completely lack tumorigenicity,
culturing the same cells in DF medium for 2 or 3 months, in a
time-dependent manner, restores their tumor-initiating capacity
(Fig. 8B). Furthermore, treatment of Du145-VP16 cells with 59-
aza-deoxycytidine for as short as 72 h significantly increases their
tumorigenic potential. At the molecular level, treatment of DTCs
with TSA or Aza increases the protein levels of CD44, E-cadherin,
and KDM5A, indicating strongly that chronic drug exposure has
altered the epigenetic landscape and chromatin state in Du145
cells. These observations, which are remarkably similar to the
Figure 8. ‘Stemness’ gene expression profiles and epigenetic mechanisms in Du145-VP16 cells. A. Du145-VP16 cells show both
decreases and increases in stemness gene expression levels. The mRNA levels of the indicated genes in parental Du145 (set at 1, blue bars) and
Du145-VP16 (red bars) cells were determined by qPCR. P values were indicated for those genes that showed statistically significant differences. B.
Tumor incidence in various types of Du145-VP16 cells implanted (10,000) in NOD/SCID mice. As shown in Table 1, parental Du145 cells showed 100%
incidence at 10,000 cells whereas Du145-VP16 cells failed to initiate tumors. When cultured in drug-free (DF) medium for 2 and 3 months, increased
tumor incidence was observed (**P,0.01 compared with Du145-VP16). When Du145-VP16 cells treated with Aza (0.1 mM, 72 h) were injected,
increased tumor incidence was also observed (*P,0.05 when compared with Du145-VP16 cells). C–D. Du145-VP16 cells treated with the indicated
chemicals (72 h) were used in Western blotting analysis of CD44, KDM5A, and E-cadherin. b-Actin was used as loading control.
doi:10.1371/journal.pone.0024397.g008
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tolerant lung cancer cells during their acute response to
chemotherapeutic drugs and tyrosine kinase inhibitors [50],
suggest that the loss of tumorigenicity in chronic drug-selected
Du145 cells is ‘transient’ and reversible. These results further bear
resemblance to the emerging evidence that cancer cells can
cyclically lose and regain drug-resistant CSC features and
properties [62]. Finally, our findings provide some mechanistic
insight on the current metronomic chemotherapy and imply that
continuous administration of low doses of chemodrugs can keep
drug-tolerant cancer cells at bay and prevent them from
regenerating tumors. Because the drug-tolerant Du145 cells have
undergone multiple epigenetic changes (Fig. 8), understandably,
CD44 overexpression alone can only partially restore the
tumorigenic potential of Du145-VP16 cells and CD44 knockdown
in parent Du145 cells, despite inhibiting cell proliferation and
tumor regeneration, does not render cells resistant to drugs (Chen
et al., unpublished observations).
How should we reconcile the current findings with other studies
showing that drug-resistant cancer cells are enriched in stem-like
cancer cells [31,63,64]? In most drug-resistance studies, cancer
cells are exposed acutely to therapeutics for a short period of time,
generally up to 2 weeks. In contrast, we purposely wish to
recapitulate the metronomic chemotherapy [48] currently used in
the clinic by CHRONICALLY exposing cancer cells to drugs for
months. Presumably, the difference in drug-selection protocols
(i.e., the dose of drugs and duration of exposure) has led to more or
less tumorigenic cancer cells. It is interesting to note that etoposide
and taxanes are among the few chemotherapy drugs that have
demonstrated some clinical efficacy for advanced PCa patients. It
is currently unclear how etoposide and paclitaxel, which possess
quite different modes of action, preferentially ablate the CD44
+
Du145 cells. If the clinical efficacy of these two drugs is associated
with their ability to target the CD44
+ PCa cells and if CSCs, as
hypothesized, represent the cells at the root of tumor maintenance,
progression, recurrence, and metastasis, why cannot etoposide and
paclitaxel completely ablate the tumors and cure the patients? One
possibility is related to inefficient delivery of drugs such that they
cannot reach all CD44
+ cells in the tumor. Another possibility is
that PCa cells may possess some plasticity and CD44
2 PCa might
revert to CD44
+ PCa cells. Indeed, CD44
2 Du145-VP16 cells,
after culturing in DF medium for 3 months, contain nearly as
many CD44
+ cells as in the parent Du145 cultures (unpublished
observations). Future studies on DTCs should shed important light
on the cellular, molecular, and epigenetic mechanisms of cancer
cell drug resistance.
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